The Phase III portion of the companies’ trial of Kevzara will now only enroll critically ill patients and randomize them to receive the drug at 400mg or placebo, after the drug did not appear effective in severely ill patients.

LEAVE A REPLY

Please enter your comment!
Please enter your name here